Revisiting VEGF/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?
Authors:
- 23 May 2025
- journal article
- review article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (9) , 1471-1494
Abstract
Angiogenesis plays an important role in tumor growth and metastasis. Targeting tumor vascular endothelial cells to inhibit tumor angiogenesis and thus block tumor blood and nutrition supply is the current research focus on anti-tumor growth and metastasis. Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2) signal pathway regulates the proliferation, migration, survival and angiogenesis of vascular endothelial cells, which is abnormally activated in different tumors. Studies have confirmed that inhibiting VEGF/VEGFR-2 signaling pathway can produce anti-tumor effect. Nowadays, anti-angiogenesis therapy targeting VEGF/VEGFR-2 inhibition has become the most effective clinical strategy for cancer treatment. Therefore, a variety of VEGF/VEGFR-2 inhibitors with different structures have been developed. A few selectively inhibit VEGF to block the activation of VEGFR-2 pathway, while the majority selectively inhibit VEGFR-2 as multi-target inhibitors. Based on the classification of dominant skeletons, this paper briefly analyzes the biological activity, clinical research process and structure-activity relationship of the representative small molecule inhibitors of VEGF/VEGFR-2.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (2632018ZD09)
- College Students Innovation Project for the R&D of Novel Drugs (2025103161142)
This publication has 129 references indexed in Scilit:
- Benzofuran‐Chalcone Derivatives as VEGFR‐2 Inhibitors: Synthesis and Anticancer EvaluationChemistry & Biodiversity, 2024
- Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activityArchiv der Pharmazie, 2023
- Synthesis of new thienylnicotinamidines: Proapoptotic profile and cell cycle arrest of HepG2 cellsArchiv der Pharmazie, 2022
- New 2,4‐disubstituted‐2‐thiopyrimidines as VEGFR‐2 inhibitors: Design, synthesis, and biological evaluationArchiv der Pharmazie, 2019
- Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMDJournal of Cellular Physiology, 2019
- Design, synthesis, and docking study of new quinoline derivatives as antitumor agentsArchiv der Pharmazie, 2019
- Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/METInternational Journal of Cancer, 2018
- Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR‐2 InhibitorsArchiv der Pharmazie, 2017
- Mechanisms of resistance to vascular endothelial growth factor blockadeCancer, 2011
- Vascular endothelial growth factors VEGF-B and VEGF-CJournal of Cellular Physiology, 1997